Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s What Happened

Mainz Biomed (NASDAQ:MYNZ)’s stock price was down 5.3% on Wednesday . The stock traded as low as $4.24 and last traded at $4.32. Approximately 53,969 shares traded hands during trading, an increase of 22% from the average daily volume of 44,295 shares. The stock had previously closed at $4.56.

Analysts Set New Price Targets

Separately, HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday, November 25th.

Mainz Biomed Stock Down 0.5 %

The stock has a market cap of $8.60 million, a P/E ratio of -0.07 and a beta of 0.06. The company’s 50 day moving average price is $7.52 and its two-hundred day moving average price is $11.76.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.